TOP > 外国特許検索 > IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION

IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION NEW

外国特許コード F170009266
整理番号 (S2016-0507-N0)
掲載日 2017年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP010437
国際公開番号 WO 2017159736
国際出願日 平成29年3月15日(2017.3.15)
国際公開日 平成29年9月21日(2017.9.21)
優先権データ
  • 特願2016-053913 (2016.3.17) JP
発明の名称 (英語) IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION NEW
発明の概要(英語) The present invention addresses the problem of providing: an immunocompetent cell in which regulatory factors of immune function from immunocompetent cells are expressed in the immunocompetent cell, and which combines proliferative capacity, viability, and a capacity for T-cell accumulation; and an immune function regulatory factor expression vector for preparing said immunocompetent cell. An immunocompetent cell is prepared which expresses interleukin 7 (IL-7), CCL19, and a cell surface molecule for specifically recognizing cancer antigens. The cell surface molecule for specifically recognizing cancer antigens is preferably a T-cell receptor that specifically recognizes cancer antigens, and the immunocompetent cell is preferably a T-cell.
特許請求の範囲(英語) [claim1]
1. The cell surface molecule which recognizes the cancer antigen uniquely, interleukin 7 (IL-7), and the immunity charge cell which reveals CCL19.
[claim2]
2. The cell surface molecule which recognizes the cancer antigen uniquely, the immunity charge cell of the claim 1 statement which features that it is the T cell receptor which recognizes the cancer antigen uniquely.
[claim3]
3. The claim the immunity charge cell of 1 which features that the immunity charge cell is the T cell or 2 statements.
[claim4]
4. The cancer antigen, either of the claim 1-3 which features that it is WT1, MART-1, NY-ESO-1, MAGE-A1, MAGE-A3, MAGE-A4, Glypican-3, KIF20A, Survivin, AFP-1, gp100, MUC1, PAP-10, PAP-5, TRP2-1, SART-1, VEGFR1, VEGFR2, NEIL3, MPHOSPH1, DEPDC1, FOXM1, CDH3, TTK, TOMM34, URLC10, KOC1, UBE2T, TOPK, ECT2, MESOTHELIN, NKG2D, P1A, GD2 or GM2 in 1 sections the immunity charge cell of statement.
[claim5]
5. Either of the claim 1-4 (a) below in order to produce the immunity charge cell of statement in 1 sections the - (e) no manifestation vector.
(A) The manifestation vector which contains the nuclear acid which nuclear acid, and CCL19 which nuclear acid and IL-7 which the cell surface molecule which recognizes the cancer antigen uniquely the cord/code are done the cord/code are done the cord/code is done:
(B) (B-1) below and (b-2) two manifestation vectors:
(B-1) The manifestation vector which contains the nuclear acid which the cell surface molecule which recognizes the cancer antigen uniquely the cord/code is done;
(B-2) The manifestation vector which contains the nuclear acid which nuclear acid, and CCL19 which IL-7 the cord/code are done the cord/code is done;
(C) (C-1) below and (c-2) two manifestation vectors:
(C-1) The manifestation vector which contains the nuclear acid which nuclear acid, and IL-7 which the cell surface molecule which recognizes the cancer antigen uniquely the cord/code are done the cord/code is done;
(C-2) The manifestation vector which contains the nuclear acid which CCL19 the cord/code is done;
(D) (D-1) below and (d-2) two manifestation vectors:
(D-1) The manifestation vector which contains the nuclear acid which IL-7 the cord/code is done;
(D-2) The manifestation vector which contains the nuclear acid which nuclear acid, and CCL19 which the cell surface molecule which recognizes the cancer antigen uniquely the cord/code are done the cord/code is done;
(E) (E-1) below, (e-2) and (e-3) three manifestation vectors:
(E-1) The manifestation vector which contains the nuclear acid which the cell surface molecule which recognizes the cancer antigen uniquely the cord/code is done;
(E-2) The manifestation vector which contains the nuclear acid which IL-7 the cord/code is done;
(E-3) The manifestation vector which contains the nuclear acid which CCL19 the cord/code is done;
[claim6]
6. The cell surface molecule which recognizes the cancer antigen uniquely, the manifestation vector of the claim 5 statement which features that it is the T cell receptor which recognizes the cancer antigen uniquely.
[claim7]
7. (A) In the manifestation vector, the nuclear acid which nuclear acid, and CCL19 which nuclear acid and IL-7 which the cell surface molecule which recognizes the cancer antigen uniquely the cord/code are done the cord/code are done the cord/code is done,
(B-2) In the manifestation vector, the nuclear acid which nuclear acid, and CCL19 which IL-7 the cord/code are done the cord/code is done,
(C-1) In the manifestation vector, the nuclear acid which nuclear acid, and IL-7 which the cell surface molecule which recognizes the cancer antigen uniquely the cord/code are done the cord/code is done, or
(D-2) In the manifestation vector, the nuclear acid which nuclear acid, and CCL19 which the cell surface molecule which recognizes the cancer antigen uniquely the cord/code are done the cord/code is done,
Through self cutting type peptide, the claim the manifestation vector of 5 which features that it is connected or 6 statements.
[claim8]
8. Either of the claim 5-7 which features that the nuclear acid which the suicide gene the cord/code is done is contained in 1 sections the manifestation vector of statement.
[claim9]
9. Either of the claim 1-4 the carcinostatic substance which contains with the immunity charge cell of statement and the additive which is allowed pharmacy in 1 sections.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • YAMAGUCHIUNIVERSITY
  • 発明者(英語)
  • TAMADA KOJI
  • SAKODA YUKIMI
  • ADACHI KEISHI
国際特許分類(IPC)
指定国 (WO2017159736)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close